Science Corporation has successfully performed a PRIMA retinal implant on a patient with Stargardt disease, a rare condition leading to vision loss. This clinical trial milestone advances the company’s neurotechnology efforts. Please note that Science Corporation is a private company and not listed on any public stock exchange.
Clinical Milestone in Vision Restoration
Science Corporation has achieved a new milestone in its clinical development program, successfully performing a PRIMA retinal implant in a patient diagnosed with Stargardt disease. This condition causes the gradual loss of central vision due to the degeneration of light-sensing cells in the retina. The PRIMA system, which involves a two-millimeter square implant placed under the retina, functions as an artificial photoreceptor. It works in conjunction with camera-equipped glasses that transmit visual data directly to the brain via electrical signals, potentially helping patients restore partial central vision.
Corporate Context and Private Status
While this development marks a significant research achievement, it is essential for investors to note that Science Corporation is a private, clinical-stage neurotechnology firm. It is not currently listed on any public stock exchange in India or abroad. Consequently, the company has no share price, public trading history, or exchange filings.
The company reached a valuation of $1.5 billion following a $230 million Series C funding round in March 2026. Given its private status, direct investment in the company is typically limited to institutional investors or through private equity channels, rather than public stock market participation.
Commercial Progress and Regulatory Path
Although the Stargardt disease application is a focus of ongoing clinical trials, the company’s immediate commercial path centers on a different condition. In July 2026, Science Corporation received a CE mark for the PRIMA retinal implant specifically for treating geographic atrophy caused by dry age-related macular degeneration (AMD). Following this regulatory approval, the company began a commercial launch in European markets, with initial implementations in countries like Germany.
This distinction is important, as the application for Stargardt disease represents an expansion of the device's potential, distinct from its current commercial approval for AMD. The company is now navigating the complexities of scaling this technology for wider clinical use.
Risks and Monitorables
Investors tracking the progress of advanced medical device firms should be aware of several inherent risks. As a clinical-stage company, Science Corporation faces the challenge of securing regulatory approvals in major markets, including the United States, where FDA clearance is required before the device can be commercialized.
Beyond regulatory hurdles, the company must manage the operational risks associated with medical device commercialization, such as securing insurance reimbursement for patients, ensuring adoption by eye care specialists, and managing the long-term clinical outcomes of patients. Development of brain-computer interface technology involves significant research and development costs and the potential for clinical trial results that may differ from initial expectations. The company's future value will depend on its ability to successfully commercialize its current product in Europe, obtain approvals in other regions, and demonstrate the safety and efficacy of its technology across different ocular conditions.